Cargando…

Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations

Long-term glucocorticoid therapy has improved outcomes in patients with Duchenne muscular dystrophy. However, the recommended glucocorticoid dosage suppresses the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency that may develop during severe illness, trauma or surgery, and afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowden, Sasigarn A., Connolly, Anne M., Kinnett, Kathi, Zeitler, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398538/
https://www.ncbi.nlm.nih.gov/pubmed/30614808
http://dx.doi.org/10.3233/JND-180346
_version_ 1783399597860716544
author Bowden, Sasigarn A.
Connolly, Anne M.
Kinnett, Kathi
Zeitler, Philip S.
author_facet Bowden, Sasigarn A.
Connolly, Anne M.
Kinnett, Kathi
Zeitler, Philip S.
author_sort Bowden, Sasigarn A.
collection PubMed
description Long-term glucocorticoid therapy has improved outcomes in patients with Duchenne muscular dystrophy. However, the recommended glucocorticoid dosage suppresses the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency that may develop during severe illness, trauma or surgery, and after discontinuation of glucocorticoid therapy. The purpose of this review is to highlight the risk of adrenal insufficiency in this patient population, and provide practical recommendations for management of adrenal insufficiency, glucocorticoid withdrawal, and adrenal function testing. Strategies to increase awareness among patients, families, and health care providers are also discussed.
format Online
Article
Text
id pubmed-6398538
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-63985382019-03-06 Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations Bowden, Sasigarn A. Connolly, Anne M. Kinnett, Kathi Zeitler, Philip S. J Neuromuscul Dis Review Long-term glucocorticoid therapy has improved outcomes in patients with Duchenne muscular dystrophy. However, the recommended glucocorticoid dosage suppresses the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency that may develop during severe illness, trauma or surgery, and after discontinuation of glucocorticoid therapy. The purpose of this review is to highlight the risk of adrenal insufficiency in this patient population, and provide practical recommendations for management of adrenal insufficiency, glucocorticoid withdrawal, and adrenal function testing. Strategies to increase awareness among patients, families, and health care providers are also discussed. IOS Press 2019-01-30 /pmc/articles/PMC6398538/ /pubmed/30614808 http://dx.doi.org/10.3233/JND-180346 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bowden, Sasigarn A.
Connolly, Anne M.
Kinnett, Kathi
Zeitler, Philip S.
Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title_full Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title_fullStr Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title_full_unstemmed Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title_short Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
title_sort management of adrenal insufficiency risk after long-term systemic glucocorticoid therapy in duchenne muscular dystrophy: clinical practice recommendations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398538/
https://www.ncbi.nlm.nih.gov/pubmed/30614808
http://dx.doi.org/10.3233/JND-180346
work_keys_str_mv AT bowdensasigarna managementofadrenalinsufficiencyriskafterlongtermsystemicglucocorticoidtherapyinduchennemusculardystrophyclinicalpracticerecommendations
AT connollyannem managementofadrenalinsufficiencyriskafterlongtermsystemicglucocorticoidtherapyinduchennemusculardystrophyclinicalpracticerecommendations
AT kinnettkathi managementofadrenalinsufficiencyriskafterlongtermsystemicglucocorticoidtherapyinduchennemusculardystrophyclinicalpracticerecommendations
AT zeitlerphilips managementofadrenalinsufficiencyriskafterlongtermsystemicglucocorticoidtherapyinduchennemusculardystrophyclinicalpracticerecommendations